Artificially designed hepatitis B virus core particles composed of multiple epitopes of type A and O foot‐and‐mouth disease virus as a bivalent vaccine candidate

Recently, many countries, including China, have experienced a series of type A and O foot‐and‐mouth disease virus (FMDV) epidemics, causing serious economic losses. Although concerns about the safety of inactivated FMD vaccines have been raised, the development of a safe and effective subunit vaccine is necessary. We constructed two chimeric virus‐like particles (VLPs; rHBc/AO and rHBc/AOT VLPs) displaying tandem repeats of B cell epitopes (VP1 residue 134‐161 and 200‐213) derived from type A and O FMDV and one T cell epitope (3 A residue 21‐35) using the truncated hepatitis B virus core (HBc) carrier. Our results indicate that the chimeric HBc can self‐assemble into VLPs with these FMDV epitopes displayed on the surface. Immunization with the chimeric VLPs induced specific IgG and neutralization antibodies against type A and O FMDV in mice. Compared with the commercial type A/O FMDV bivalent inactivated vaccine, rHBc/AO and rHBc/AOT VLPs significantly stimulated the production of Th1 type cytokines (IFN‐γ and IL‐2), whereas Th2 cytokine production (IL‐4 and IL‐10) was decreased. Compared with rHBc/AO, rHBc/AOT induced increased Th2 cytokine and specific IgG production. These results demonstrate that the VLPs constructed in the current study induced both humoral and cellular immune responses and may represent potential bivalent VLP vaccines targeting both FMDV type A and O strains.

[1]  Rui-tian Liu,et al.  Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer’s disease and frontotemporal dementia , 2018, Alzheimer's Research & Therapy.

[2]  Gaiping Zhang,et al.  Immunogenicity evaluation of MS2 phage-mediated chimeric nanoparticle displaying an immunodominant B cell epitope of foot-and-mouth disease virus , 2018, PeerJ.

[3]  D. Andreu,et al.  Immune Response and Partial Protection against Heterologous Foot-and-Mouth Disease Virus Induced by Dendrimer Peptides in Cattle , 2018, Journal of immunology research.

[4]  L. Lei,et al.  Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice. , 2017, Vaccine.

[5]  W. Tan,et al.  Virus like particles as a platform for cancer vaccine development , 2017, PeerJ.

[6]  Yongguang Zhang,et al.  Lithium chloride inhibits early stages of foot‐and‐mouth disease virus (FMDV) replication in vitro , 2017, Journal of medical virology.

[7]  G. Medina,et al.  Foot-and-mouth disease vaccines. , 2017, Veterinary microbiology.

[8]  Hai Yu,et al.  A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus. , 2017, Vaccine.

[9]  Lifang Zhang,et al.  Major Immunodominant Region of Hepatitis B Virus Core Antigen as a Delivery Vector to Improve the Immunogenicity of the Fusion Antigen ROP2-SAG1 Multiepitope from Toxoplasma gondii in Mice. , 2017, Viral immunology.

[10]  Qifeng Bai,et al.  Rational design and efficacy of a multi‐epitope recombinant protein vaccine against foot‐and‐mouth disease virus serotype A in pigs , 2017, Antiviral research.

[11]  Decheng Yang,et al.  Identification of a conserved conformational epitope in the VP2 protein of foot-and-mouth disease virus , 2017, Archives of Virology.

[12]  Yun-Jaie Choi,et al.  Artificially designed recombinant protein composed of multiple epitopes of foot-and-mouth disease virus as a vaccine candidate , 2017, Microbial Cell Factories.

[13]  Y. Zhang,et al.  Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection. , 2016, Antiviral research.

[14]  B. Charleston,et al.  Global Foot-and-Mouth Disease Research Update and Gap Analysis: 4 - Diagnostics. , 2016, Transboundary and emerging diseases.

[15]  Weiwei Huang,et al.  Chimeric HBcAg virus-like particles presenting a HPV 16 E7 epitope significantly suppressed tumor progression through preventive or therapeutic immunization in a TC-1-grafted mouse model , 2016, International journal of nanomedicine.

[16]  D. Andreu,et al.  Full protection of swine against foot-and-mouth disease by a bivalent B-cell epitope dendrimer peptide. , 2016, Antiviral research.

[17]  Jiaoyan Ren,et al.  Design of nanomaterial based systems for novel vaccine development. , 2016, Biomaterials science.

[18]  Yi-mei Cao,et al.  Foot-and-mouth disease vaccines: progress and problems , 2016, Expert review of vaccines.

[19]  Azam Bolhassani,et al.  Different applications of virus‐like particles in biology and medicine: Vaccination and delivery systems , 2015, Biopolymers.

[20]  Istvan Toth,et al.  Recent advances in peptide-based subunit nanovaccines. , 2014, Nanomedicine.

[21]  M. Joshi,et al.  Peptide Vaccine: Progress and Challenges , 2014, Vaccines.

[22]  D. Andreu,et al.  B Epitope Multiplicity and B/T Epitope Orientation Influence Immunogenicity of Foot-and-Mouth Disease Peptide Vaccines , 2013, Clinical & developmental immunology.

[23]  J. Rushton,et al.  The economic impacts of foot and mouth disease – What are they, how big are they and where do they occur? , 2013, Preventive veterinary medicine.

[24]  C. Guzmán,et al.  Vaccines: From Empirical Development to Rational Design , 2012, PLoS pathogens.

[25]  Jun-jun Shao,et al.  Immune potential of a novel multiple-epitope vaccine to FMDV type Asia 1 in guinea pigs and sheep , 2011, Virologica Sinica.

[26]  Marianne Manchester,et al.  Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine design , 2010, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[27]  M. Grubman,et al.  Foot and mouth disease virus vaccines. , 2009, Vaccine.

[28]  H. Thulke,et al.  High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus. , 2008, Vaccine.

[29]  Xiangguo Duan,et al.  Heterologous expression of FMDV immunodominant epitopes and HSP70 in P. pastoris and the subsequent immune response in mice. , 2007, Veterinary microbiology.

[30]  B. Charleston,et al.  Global FMD control--is it an option? , 2007, Vaccine.

[31]  B. Baxt,et al.  Foot-and-Mouth Disease , 2004, Clinical Microbiology Reviews.

[32]  S. Cleaveland,et al.  Molecular epidemiology of foot-and-mouth disease virus. , 2003, Virus research.

[33]  E. Domingo,et al.  Foot-and-mouth disease virus. , 2002, Comparative immunology, microbiology and infectious diseases.

[34]  N. Knowles,et al.  Foot-and-mouth disease type O viruses exhibit genetically and geographically distinct evolutionary lineages (topotypes). , 2001, The Journal of general virology.

[35]  E. Domingo,et al.  Direct evaluation of the immunodominance of a major antigenic site of foot-and-mouth disease virus in a natural host. , 1995, Virology.

[36]  B. Clarke,et al.  Epitope mapping of foot-and-mouth disease virus with neutralizing monoclonal antibodies. , 1989, The Journal of general virology.

[37]  Richard A. Houghten,et al.  Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence , 1982, Nature.